1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate

CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O

InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1

HYFHYPWGAURHIV-JFIAXGOJSA-N

homoharringtonine; Omacetaxine mepesuccinate; 26833-87-4; Ceflatonin; Myelostat; Synribo; CGX-635; Omapro; Homoharringtonin; (-)-homoharringtonine; NSC-141633; C29H39NO9; CHEBI:71019; (2'R,3S,4S,5R)-(-)-homoharringtonine; Omacetaxine (homoharringtonine); Omacetaxine mepesuccinate [USAN]; 6FG8041S5B; NSC 141633; 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate; Cephalotaxine 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate; Omacetaxine mepesuccinate (USAN); Tekinex; Synribo (TN); Cephalotaxine, 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester); UNII-6FG8041S5B; NSC141633; NCGC00025155-01; Omacetaxine mepesuccinate [USAN:INN]; BRN 5687925; omacetaxini mepesuccinas; ZJ-C; mepesuccinate d'omacetaxine; mepesuccinato de omacetaxina; Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester); MLS001424293; CHEMBL46286; HOMOHARRINGTONINE [MI]; CGX-635-14 (formulation); GTPL7454; SCHEMBL12745687; HMS3267H22; HMS3414N05; HMS3678N03; AMY33459; Homoharringtonine, >=98% (HPLC); BDBM50480293; HB4660; MFCD05618221; NSC758253; s9015; ZINC26011099; AKOS024456585; CCG-269981; DB04865; NC00395; NSC-758253; OMACETAXINE MEPESUCCINATE [INN]; NCGC00025155-02; NCGC00025155-03; NCGC00025155-04; NCGC00025155-07; OMACETAXINE MEPESUCCINATE [MART.]; OMACETAXINE MEPESUCCINATE [VANDF]; HY-14944; NCI60_000917; OMACETAXINE MEPESUCCINATE [WHO-DD]; SMR000469230; H1775; D08956; OMACETAXINE MEPESUCCINATE [ORANGE BOOK]; AB00642561-02; EN300-22161068; SR-01000597562; Q7089373; SR-01000597562-1; BRD-K76674262-001-01-7; BRD-K76674262-001-02-5; Cephalotaxine, 3-[4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate]; Cephalotaxine, 4-methyl-, 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester); (2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0^{2,6}.0^{6,10}.0^{15,19}]icosa-1(13),4,14,19-tetraen-3-yl 1-methyl (3R)-3-hydroxy-3-(4-hydroxy-4-methylpentyl)butanedioate; (S)-1-((11bS,12S,14aR)-13-methoxy-2,3,5,6,11b,12-hexahydro-1H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-12-yl) 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)succinate; 1-((1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H- cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2R)-2- hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate; 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate; Homoharringtonine; Cephalotaxine; [3(R)]-4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate